Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Cash & Current Investments (2020 - 2026)

BioScience Health Innovations has reported Cash & Current Investments over the past 7 years, most recently at $1.1 million for Q1 2026.

  • Quarterly Cash & Current Investments rose 11.34% to $1.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Mar 2026, up 11.34% year-over-year, with the annual reading at $661925.0 for FY2025, 0.09% changed from the prior year.
  • Cash & Current Investments was $1.1 million for Q1 2026 at BioScience Health Innovations, up from $661925.0 in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $1.3 million in Q2 2025 and troughed at $9464.0 in Q1 2023.
  • The 5-year median for Cash & Current Investments is $92935.0 (2024), against an average of $396933.1.
  • The largest YoY upside for Cash & Current Investments was 6439.04% in 2022 against a maximum downside of 70.52% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $28343.0 in 2022, then crashed by 32.12% to $19238.0 in 2023, then soared by 3343.79% to $662517.0 in 2024, then fell by 0.09% to $661925.0 in 2025, then surged by 72.98% to $1.1 million in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Cash & Current Investments are $1.1 million (Q1 2026), $661925.0 (Q4 2025), and $1.1 million (Q3 2025).